Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.26 USD | -1.31% | +1.77% | -33.32% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.4 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.65 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.28% | 3.23B | C- | ||
+19.22% | 84.52B | C+ | ||
-27.14% | 72.21B | B- | ||
+4.65% | 27.74B | C+ | ||
-6.23% | 17.97B | B | ||
-0.32% | 17.46B | A- | ||
+3.30% | 15.82B | A- | ||
+7.44% | 13.55B | B- | ||
+6.56% | 13.31B | A- | ||
+73.32% | 13.32B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SHC Stock
- Ratings Sotera Health Company